君实生物JS001sc一线治疗非鳞状非小细胞肺癌的Ⅲ期临床研究达到主要研究终点

Core Viewpoint - Junshi Biosciences (688180) announced that its product Toripalimab injection (subcutaneous) (code: JS001sc) achieved the primary research endpoint in a Phase III clinical study for the treatment of recurrent or metastatic non-squamous non-small cell lung cancer in combination with chemotherapy, compared to Toripalimab injection (trade name: Tuoyi, product code: JS001) [1] Group 1 - The company plans to submit a marketing authorization application for JS001sc to regulatory authorities in the near future [1] - JS001sc is developed based on the already marketed product Toripalimab injection and is the first domestic PD-1 monoclonal antibody subcutaneous formulation to enter Phase III clinical research [1] - The new formulation is expected to provide convenience for patients in terms of medication administration [1]